Pharma BD Deal Intelligence
Nestlé's ~$2.5B carve-out of Novartis Medical Nutrition (Boost, Optifast, Resource) made it the world's number-two clinical-nutrition player and seeded the 2011 launch of Nestlé Health Science. But the unit's later growth to CHF 6.5B+ came mostly from subsequent bolt-ons, not the original assets, and post-merger culture clashes between Novartis's multi-local model and Nestlé's global rollout were real—leaving the original deal's standalone ROI undisclosed.
Became the seed asset for Nestlé Health Science, but no public evidence the $2.5B price paid off on its own economics; culture-clash integration was documented as a real, non-trivial problem.
Full analysis, sources & comparables →Nestle agreed to buy Novartis Medical Nutrition for $2.5B, strengthening its #2 position behind Abbott in clinical nutrition and continuing its push into…
Nestle confirmed the US$2.5bn purchase of Novartis Medical Nutrition, covering oral and tube-delivery nutritional supplements for hospitals and nursing homes;…
Nestle completed the $2.5B acquisition on July 2, 2007 after EU regulatory review, elevating it to a 'very strong player in the strategic core category of…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Nestle SA acquired Novartis Medical Nutrition for approximately $2.5 billion (announced December 2006, completed July 2007 following regulatory review), adding the Optifast, Boost and Resource clinical-nutrition brands — a unit generating roughly $950 million in annual sales — and making Nestle the world's number-two player in healthcare nutrition behind Abbott. The divestiture allowed Novartis to refocus on its core pharmaceuticals business. Note: this is a medical-nutrition transaction, borderline relative to core pharma.
Became the seed asset for Nestlé Health Science, but no public evidence the $2.5B price paid off on its own economics; culture-clash integration was documented as a real, non-trivial problem.
Assessment window: 15yr post-close.
$950M Novartis Medical Nutrition 2006 global sales (USD) · 2,000 Employees joining Nestle
Medical nutrition serves patients with conditions that compromise normal nutrient intake or absorption — including hospitalized patients, the elderly, oncology patients, and those with metabolic disorders or eating disorders. Products span enteral tube feeding, oral nutritional supplements, and specialized formulas for diabetes, renal disease, dysphagia, and weight management.
The 2006 medical nutrition category was led by Abbott Nutrition (Ensure, Glucerna, Jevity) and Numico (Nutricia, Milupa) before Danone acquired Numico in 2007. Novartis Medical Nutrition was the worldwide #2 with 2006 sales of ~$950 million, anchored by Boost (oral nutritional supplement competing with Ensure), Resource (clinical/disease-specific formulas) and Optifast (medically supervised weight management). Pre-deal, Nestle was a peripheral player in adult medical nutrition; the $2.5B acquisition vaulted Nestle into the global #2 position behind Abbott and reshaped the competitive set into a three-way race (Abbott / Nestle / Danone-Nutricia) that persists today. Strategically the deal extended Nestle's 'Nutrition, Health and Wellness' transformation announced under CEO Peter Brabeck-Letmathe, complementing the parallel $5.5B Gerber baby-food acquisition from Novartis. Note: medical nutrition straddles the pharma/consumer boundary — products are typically reimbursed in institutional settings but sold OTC for retail SKUs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nestle SA / Novartis Medical Nutrition (this deal) | 2006 | $2.5B | 64 |
| Nestle SA / Pfizer Nutrition (Pfizer Inc. infant nutrition unit) | 2012 | $11.8B | 50 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals